Market Research Report
Japan Digital Genome Market Forecast 2021-2026
|Published by||Inkwood Research||Product code||991381|
|Published||Content info||109 Pages
Delivery time: 2-3 business days
|Japan Digital Genome Market Forecast 2021-2026|
|Published: March 1, 2021||Content info: 109 Pages||
The Japan digital genome market is anticipated to record a CAGR of 10.43%, across the forecast period. The augmenting healthcare system, the investments and initiatives undertaken by the governments, and the enhanced technological developments for gene editing, are anticipated to fuel the country's market growth. The base year considered for the studied market is 2020, while the forecast years from 2021 to 2026.
In February 2018, the government of Japan appointed 11 hospitals across the country to serve as core hospitals for cancer genomic medicine. Similarly, the government also delegated 100 facilities, as associated hospitals, to work in collaboration with core hospitals. As a result, the partnership would offer cancer genomic medicine under the national health insurance system. The genome project termed, Initiative on Rare and Undiagnosed Diseases (IRUD), was launched in 2015, aiming to diagnose patients with rare diseases in the country. Moreover, the IRUD receives annual grants ranging from ¥600 million to ¥700 million.
Japan is also willing to reinforce efforts to develop its technology for genome editing. In this regard, Japan's Economy, Trade, and Industry Ministry has allocated nearly $76,995,450, for the years 2016 to 2020. The investment would improve the development for treating stubborn diseases, such as, AIDS and hemophilia, and to modify crops and livestock genetically. Hence, these factors are set to propel the country's digital genome market growth during the forecast period.
Some of the key players operating in the country's market are, Bio-Rad Laboratories Inc, Abbott Laboratories, Illumina Inc, Thermo Fisher Scientific Inc, Becton, Dickinson and Company (BD), etc.